NASDAQ · IONS
Ionis Pharmaceuticals, Inc.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
Loading market information…
NASDAQ · DYN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Dyne Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.61% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Dyne Therapeutics, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.91. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Dyne Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Feb 27, 2025 |
| -$0.88+4.35% vs estimate |
| $0.00 |
| Q3 2024 | Nov 12, 2024 | -$0.96-35.21% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 10 contributors · Median target $34.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$64.46+$1.44 (+2.28%)
PTC Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
$19.23-$0.09 (-0.47%)
Sarepta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.43% below the high.
$26.35-$0.06 (-0.23%)
Stoke Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.49% below the high.
$3.63-$0.01 (-0.27%)
Wave Life Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.29% below the high.
$6.39-$0.09 (-1.39%)
Solid Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.19% below the high.
$6.63+$0.40 (+6.42%)
Capricor Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.58% below the high.
$2.67+$0.13 (+5.12%)
Larimar Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.41% below the high.
